Literature DB >> 21920970

Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.

Jakob Dörler1, Michael Edlinger, Hannes F Alber, Johann Altenberger, Werner Benzer, Georg Grimm, Kurt Huber, Otmar Pachinger, Herwig Schuchlenz, Peter Siostrzonek, Gerald Zenker, Franz Weidinger.   

Abstract

AIMS Pre-treatment with clopidogrel results in a reduction of ischaemic events in non-ST-elevation acute coronary syndromes. Data on upstream clopidogrel in the setting of primary percutaneous coronary intervention (PCI) are limited. The aim of this study was to investigate whether clopidogrel loading before arrival at the PCI centre may result in an improved outcome of primary PCI for ST-elevation myocardial infarction (STEMI). METHODS AND RESULTS In a multicentre registry of acute PCI, 5955 patients undergoing primary PCI in Austria between January 2005 and December 2009 were prospectively enrolled. The patients consisted of two groups, a clopidogrel pre-treatment group (n = 1635 patients) receiving clopidogrel before arrival at the PCI centre and a peri-interventional clopidogrel group (n = 4320 patients) receiving clopidogrel at a later stage. Multiple logistic regression analysis including major confounding factors stratified by the participating centres was applied to investigate the effect of pre-treatment with clopidogrel on the in-hospital mortality. Additionally, two subgroups, with or without the use of GP IIb/IIIa antagonist therapy in the catheterization laboratory, were analysed. On univariate analysis, clopidogrel pre-treatment was associated with a reduced in-hospital mortality (3.4 vs. 6.1%, P< 0.01) after primary PCI. On multivariate analysis, clopidogrel pre-treatment remained an independent predictor of in-hospital mortality [odds ratio (OR) = 0.60, 95% confidence interval (CI) 0.35-0.99; P =0.048], especially in patients receiving additional GP IIb/IIIa antagonist therapy in the catheterization laboratory (OR = 0.40, 95% CI 0.19-0.83; P =0.01). CONCLUSION Clopidogrel pre-treatment before arrival at the PCI centre is associated with reduced mortality in a real world setting of primary PCI. These results strongly support the recommendation of clopidogrel treatment 'as soon as possible' in patients with STEMI undergoing pimary PCI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21920970     DOI: 10.1093/eurheartj/ehr360

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  12 in total

Review 1.  Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina.

Authors:  Taylor C Bazemore; Michael G Nanna; Sunil V Rao
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

2.  [Antiplatelet therapy in acute coronary syndrome. Prehospital phase: nothing, aspirin or what?].

Authors:  T Bauer; C Hamm
Journal:  Herz       Date:  2014-11       Impact factor: 1.443

3.  Predictors of in-Hospital Mortality of ST-Segment Elevation Myocardial Infarction Patients Undergoing Interventional Treatment. An Analysis of Data from the RO-STEMI Registry.

Authors:  Diana E Cretu; Cristian A Udroiu; Claudiu I Stoicescu; Gabriel Tatu-Chitoiu; Dragos Vinereanu
Journal:  Maedica (Bucur)       Date:  2015-09

Review 4.  Clinical disease registries in acute myocardial infarction.

Authors:  Reza Ashrafi; Hussain Hussain; Robert Brisk; Leanne Boardman; Clive Weston
Journal:  World J Cardiol       Date:  2014-06-26

5.  Improved in-hospital outcome for radial access in a large contemporary cohort of primary percutaneous coronary intervention.

Authors:  Matthias Hasun; Jakob Dörler; Hannes F Alber; Axel Bauer; Rudolf Berger; Günter Christ; Matthias Frick; Uta C Hoppe; Kurt Huber; Gudrun Lamm; Elisabeth Laßnig; Dirk von Lewinski; Anna Rab; Franz X Roithinger; Herwig Schuchlenz; Peter Siostrzonek; Johann Sipötz; Thomas Stefenelli; Clemens Steinwender; Michael Edlinger; Franz Weidinger
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

Review 6.  Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization : Fifty Years of Revascularization: Where Are We and Where Are We Heading?

Authors:  Francesco Costa; Sara Ariotti; Marco Valgimigli; Philippe Kolh; Stephan Windecker
Journal:  J Cardiovasc Transl Res       Date:  2015-05-19       Impact factor: 4.132

7.  Mind the Gap: Platelet Inhibition in Low-Risk Acute Coronary Syndrome Undergoing Percutaneous Revascularization.

Authors:  Ravi K Sharma; Duane S Pinto
Journal:  J Am Heart Assoc       Date:  2019-11-26       Impact factor: 5.501

Review 8.  Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead.

Authors:  Enrico Fabris; Serge Korjian; Barry S Coller; Jurrien M Ten Berg; Christopher B Granger; C Michael Gibson; Arnoud W J van 't Hof
Journal:  Thromb Haemost       Date:  2021-04-30       Impact factor: 6.681

Review 9.  Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis.

Authors:  Anne Bellemain-Appaix; Mathieu Kerneis; Stephen A O'Connor; Johanne Silvain; Michel Cucherat; Farzin Beygui; Olivier Barthélémy; Jean-Philippe Collet; Laurent Jacq; François Bernasconi; Gilles Montalescot
Journal:  BMJ       Date:  2014-10-24

10.  Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry.

Authors:  Patrick Goldstein; Niccolò Grieco; Hüseyin Ince; Nicolas Danchin; Yvonne Ramos; Jochen Goedicke; Peter Clemmensen
Journal:  Vasc Health Risk Manag       Date:  2016-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.